Novavax analyst commentary at B. Riley FBR

Novavax added to Alpha Generator list at B. Riley FBR. B. Riley FBR analyst George Zavoico added Novavax to his firm’s Alpha Generator list based on the upcoming top-line results of two key clinical trials expected in early Q1. If a Phase III trial of ResVax delivers positive results, Novavax will seek FDA approval in 2020, the analyst points out. Further, if a Phase II trial of NanoFlu delivers positive results, Novavax could commence pivotal Phase III trial in the second half of 2020, the analyst adds. These are multi-billion-dollar markets, and positive results could make Novavax an acquisition target by a major pharmaceutical company, Zavoico tells investors in a research note. He keeps a Buy rating on the shares with a $10 price target.
https://thefly.com/landingPageNews.php?id=2800923